Boundless Bio

Boundless Bio is a company developing novel cancer therapeutics aimed at understanding and treating cancers within cells. The company aspires to be the first biopharmaceutical firm to challenge the biology of extrachromosomal DNA (ecDNA), offering transformative therapies for previously difficult-to-treat cancer patients. When DNA in cancer cells detaches from chromosomes, "extrachromosomal DNA (ecDNA)" becomes loose, allowing numerous copies of oncogenes to replicate, promoting cancer cell growth and enabling resistance to treatment. We are committed to countering this ecDNA phenomenon by developing powerful new anti-cancer drugs that eliminate the ability of cancer cells to use ecDNA for survival.